<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" version="2.0">

<channel>
	<title>Medchrome</title>
	<atom:link href="https://medchrome.com/feed/" rel="self" type="application/rss+xml"/>
	<link>https://medchrome.com</link>
	<description></description>
	<lastBuildDate>Sun, 15 Nov 2026 03:43:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://medchrome.com/wp-content/uploads/2019/09/cropped-android-chrome-512x512-32x32.png</url>
	<title>Medchrome</title>
	<link>https://medchrome.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<xhtml:meta content="noindex" name="robots" xmlns:xhtml="http://www.w3.org/1999/xhtml"/><item>
		<title>Why Healthcare Facilities Are Turning to Outsourced Psychiatric Staffing</title>
		<link>https://medchrome.com/extras/why-healthcare-facilities-are-turning-to-outsourced-psychiatric-staffing/</link>
		
		<dc:creator><![CDATA[Editor]]></dc:creator>
		<pubDate>Sun, 15 Nov 2026 03:43:53 +0000</pubDate>
				<category><![CDATA[Extras]]></category>
		<guid isPermaLink="false">https://medchrome.com/?p=14792</guid>

					<description><![CDATA[Healthcare facilities across the United States are facing a growing challenge: providing timely access to qualified psychiatric professionals while managing rising operational costs and workforce [&#8230;]]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Healthcare facilities across the United States are facing a growing challenge: providing timely access to qualified psychiatric professionals while managing rising operational costs and workforce shortages. Hospitals, outpatient clinics, community mental health centers, and substance use disorder treatment facilities all need reliable psychiatric services, but maintaining a full-time, in-house psychiatric team is not always practical or financially sustainable.</p>



<p class="wp-block-paragraph">Outsourced psychiatric staffing offers an alternative. Rather than recruiting and employing permanent psychiatrists or psychiatric nurse practitioners, healthcare organizations can partner with specialized staffing providers to access qualified professionals according to their actual patient volume and coverage requirements.</p>



<p class="wp-block-paragraph">This approach allows facilities to expand psychiatric services, improve patient access, and maintain operational flexibility without taking on all the expenses and responsibilities associated with traditional employment.</p>



<h2 class="wp-block-heading">The Challenges of Maintaining an In-House Psychiatric Team</h2>



<p class="wp-block-paragraph">Recruiting and retaining psychiatric professionals can be particularly challenging for healthcare organizations. Competition for experienced psychiatrists and psychiatric mental health nurse practitioners (PMHNPs) is significant, especially in rural communities and underserved areas.</p>



<p class="wp-block-paragraph">Hiring a full-time psychiatrist involves more than an annual salary. Organizations must also consider:</p>



<ul class="wp-block-list">
<li>Employee benefits, insurance, and retirement contributions.</li>



<li>Recruitment, credentialing, and onboarding expenses.</li>



<li>Continuing education and professional development.</li>



<li>Paid leave, sick days, and other employment-related costs.</li>



<li>Administrative responsibilities and scheduling.</li>



<li>Maintaining adequate coverage during evenings, weekends, and holidays.</li>
</ul>



<p class="wp-block-paragraph">These expenses can create a substantial financial commitment, even when patient demand does not justify a full-time position.</p>



<p class="wp-block-paragraph">Smaller clinics and residential treatment facilities may need psychiatric consultations only a few days per week. Similarly, hospitals may require additional psychiatric coverage primarily during evenings, weekends, or periods of increased patient volume.</p>



<p class="wp-block-paragraph">Employing a permanent psychiatric professional for these limited requirements can result in underutilized resources and unnecessary fixed expenses.</p>



<h2 class="wp-block-heading">What Is Outsourced Psychiatric Staffing?</h2>



<p class="wp-block-paragraph">Outsourced psychiatric staffing allows healthcare organizations to access qualified psychiatric professionals through an external staffing partner rather than employing every provider directly.</p>



<p class="wp-block-paragraph">Depending on the organization&#8217;s requirements, staffing arrangements may include:</p>



<ul class="wp-block-list">
<li>Full-time or part-time psychiatrists.</li>



<li>Psychiatric nurse practitioners.</li>



<li>Scheduled outpatient psychiatric consultations.</li>



<li>Inpatient psychiatric consultations and rounding.</li>



<li>After-hours, weekend, and holiday coverage.</li>



<li>Emergency department psychiatric assessments.</li>



<li>Medication management and follow-up appointments.</li>



<li>Specialty psychiatric services, including child and adolescent psychiatry.</li>
</ul>



<p class="wp-block-paragraph">Services can be delivered through telepsychiatry or in-person arrangements, depending on the clinical requirements and available providers.</p>



<p class="wp-block-paragraph">The primary advantage is flexibility. Healthcare organizations can arrange coverage based on their patient population, operating hours, and available budget instead of committing to a permanent employee regardless of demand.</p>



<h2 class="wp-block-heading">Outsourced Psychiatric Staffing vs. Hiring Full-Time Employees</h2>



<p class="wp-block-paragraph">One of the strongest reasons healthcare organizations consider outsourced psychiatric staffing is the potential for better cost management.</p>



<p class="wp-block-paragraph">Traditional employment requires facilities to maintain a fixed financial commitment. Outsourced staffing, on the other hand, can allow organizations to purchase only the psychiatric coverage they need.</p>



<p class="wp-block-paragraph">Consider a community mental health clinic that requires psychiatric consultations for approximately 15 hours per week. Recruiting a full-time psychiatrist may not be financially justified. Through an outsourced staffing arrangement, the clinic may obtain the required clinical hours without maintaining a permanent full-time position.</p>



<p class="wp-block-paragraph">The same principle applies to hospitals that require psychiatric coverage outside regular business hours.</p>



<p class="wp-block-paragraph">Key advantages include:</p>



<p class="wp-block-paragraph"><strong>1. Reduced Fixed Employment Costs</strong></p>



<p class="wp-block-paragraph">Facilities can avoid many expenses associated with recruiting and maintaining permanent employees. Depending on the staffing agreement, organizations may also reduce administrative and recruitment burdens.</p>



<p class="wp-block-paragraph"><strong>2. Pay for the Coverage You Need</strong></p>



<p class="wp-block-paragraph">Instead of paying for a full-time position, organizations can arrange part-time, scheduled, or on-demand psychiatric coverage. This makes staffing expenses more closely aligned with actual service requirements.</p>



<p class="wp-block-paragraph"><strong>3. Flexible Scheduling</strong></p>



<p class="wp-block-paragraph">Coverage can be arranged around patient volume and operational requirements. Facilities can obtain additional psychiatric hours during busy periods without necessarily increasing their permanent workforce.</p>



<p class="wp-block-paragraph"><strong>4. Less Recruitment Pressure</strong></p>



<p class="wp-block-paragraph">An established psychiatric staffing network can help organizations access qualified providers without conducting an entirely new recruitment process every time a staffing requirement arises.</p>



<p class="wp-block-paragraph"><strong>5. Access to Specialized Professionals</strong></p>



<p class="wp-block-paragraph">Facilities may require expertise in areas such as child and adolescent psychiatry, addiction psychiatry, or other psychiatric subspecialties. A broader provider network can make it easier to identify professionals with the appropriate experience.</p>



<h2 class="wp-block-heading">Why After-Hours Psychiatric Coverage Matters</h2>



<p class="wp-block-paragraph">Psychiatric emergencies and behavioral health needs do not follow conventional business hours.</p>



<p class="wp-block-paragraph">Hospitals frequently encounter patients requiring psychiatric evaluation in emergency departments during nights, weekends, and holidays. Substance use disorder treatment facilities may also require psychiatric assessments and medication management outside regular clinic hours.</p>



<p class="wp-block-paragraph">Maintaining permanent psychiatric staff around the clock can be prohibitively expensive, particularly for facilities with relatively low overnight patient volumes.</p>



<p class="wp-block-paragraph">Outsourced psychiatric staffing provides an alternative through scheduled and on-demand coverage arrangements.</p>



<p class="wp-block-paragraph">For example, a hospital could maintain its regular daytime psychiatric services while arranging remote psychiatric consultations for evening and overnight hours. A residential treatment facility could similarly arrange access to a psychiatric provider during specific periods when clinical support is required.</p>



<p class="wp-block-paragraph">This approach helps organizations maintain access to psychiatric expertise without having to employ additional permanent staff solely to cover less predictable hours.</p>



<p class="wp-block-paragraph">Importantly, coverage arrangements should be designed around the facility&#8217;s emergency protocols, clinical responsibilities, and applicable licensing requirements.</p>



<h2 class="wp-block-heading">Telepsychiatry Makes Flexible Staffing More Accessible</h2>



<p class="wp-block-paragraph">Telepsychiatry has significantly expanded the possibilities for outsourced psychiatric staffing.</p>



<p class="wp-block-paragraph">Through secure video consultations and other approved communication methods, psychiatrists and psychiatric nurse practitioners can provide evaluations, medication management, follow-up consultations, and clinical support without being physically present at the healthcare facility.</p>



<p class="wp-block-paragraph">This is particularly beneficial for:</p>



<ul class="wp-block-list">
<li>Rural and underserved hospitals.</li>



<li>Community mental health clinics.</li>



<li>Federally Qualified Health Centers (FQHCs).</li>



<li>Substance use disorder treatment programs.</li>



<li>Residential behavioral health facilities.</li>



<li>Hospitals requiring after-hours psychiatric consultations.</li>
</ul>



<p class="wp-block-paragraph">Telepsychiatry can also reduce the logistical challenges associated with recruiting providers willing to relocate or commute to underserved locations.</p>



<p class="wp-block-paragraph">For facilities that require physical examinations, specific on-site responsibilities, or face-to-face clinical services, in-person staffing arrangements may remain necessary. A flexible staffing partner can help organizations determine which coverage model best meets their requirements.</p>



<h2 class="wp-block-heading">The Advantage of a Psychiatric Staffing Network</h2>



<p class="wp-block-paragraph">Not all outsourced staffing arrangements provide the same level of flexibility.</p>



<p class="wp-block-paragraph">A staffing agency with an established network of psychiatric professionals can offer a significant advantage over organizations that recruit providers individually for each vacancy.</p>



<p class="wp-block-paragraph">A broader network allows healthcare facilities to access different types of psychiatric professionals according to their clinical needs. This may include adult psychiatrists, child and adolescent psychiatrists, psychiatric nurse practitioners, and other specialty providers.</p>



<p class="wp-block-paragraph">An established network can also simplify the process of identifying and matching suitable professionals with healthcare facilities.</p>



<p class="wp-block-paragraph">Once a provider is selected, the facility can proceed with the necessary credentialing, privileging, and medical staff onboarding requirements. Although these processes must still meet the organization&#8217;s policies and applicable regulations, an established provider network can help reduce the time and effort involved in sourcing qualified candidates.</p>



<p class="wp-block-paragraph">Healthcare organizations should also consider continuity of care when choosing a staffing partner. Whenever possible, maintaining consistent providers helps build relationships with patients and allows psychiatric professionals to become familiar with the facility&#8217;s clinical workflows.</p>



<p class="wp-block-paragraph">Organizations evaluating different service arrangements can explore the differences between a virtual clinic model and a <a href="https://faspsych.com/blog/virtual-clinic-model-vs-psychiatry-staffing-network/">psychiatry staffing network</a> to determine which approach better supports their operational goals.</p>



<h2 class="wp-block-heading">How FasPsych Supports Healthcare Organizations</h2>



<p class="wp-block-paragraph">FasPsych helps hospitals, clinics, and behavioral health organizations address psychiatric staffing challenges through flexible telepsychiatry and psychiatric staffing solutions.</p>



<p class="wp-block-paragraph">Rather than requiring every organization to recruit and employ a permanent psychiatric team, FasPsych connects healthcare facilities with qualified psychiatrists and psychiatric nurse practitioners from its established provider network.</p>



<p class="wp-block-paragraph">Organizations can work with FasPsych to develop staffing arrangements that reflect their actual clinical requirements.</p>



<p class="wp-block-paragraph">These arrangements may include:</p>



<ul class="wp-block-list">
<li><strong>Flexible psychiatric coverage:</strong> Access to full-time, part-time, and on-demand psychiatric professionals.</li>



<li><strong>After-hours support:</strong> Additional psychiatric coverage for hospitals and facilities that need services outside conventional business hours.</li>



<li><strong>Specialty providers:</strong> Access to professionals with experience in different areas of psychiatry, including child and adolescent psychiatry.</li>



<li><strong>Telepsychiatry services:</strong> Virtual consultations, psychiatric evaluations, medication management, and follow-up care.</li>



<li><strong>In-person staffing options:</strong> Support for organizations requiring on-site psychiatric professionals for appropriate staffing needs.</li>



<li><strong>Scalable staffing arrangements:</strong> The ability to adjust coverage as patient volumes and organizational requirements change.</li>
</ul>



<p class="wp-block-paragraph">By connecting facilities with an established psychiatric staffing network, FasPsych helps organizations address provider shortages and expand psychiatric services without necessarily taking on the financial and administrative responsibilities of maintaining additional permanent employees.</p>



<p class="wp-block-paragraph">This model can be particularly useful for smaller hospitals, community clinics, and substance use disorder treatment facilities that require reliable psychiatric expertise but cannot justify a full-time psychiatric position.</p>



<h2 class="wp-block-heading">Is Outsourced Psychiatric Staffing Right for Your Facility?</h2>



<p class="wp-block-paragraph">Outsourced psychiatric staffing is not necessarily the best solution for every healthcare organization. Facilities with consistently high patient volumes and sufficient financial resources may benefit from maintaining permanent psychiatric departments.</p>



<p class="wp-block-paragraph">However, organizations with variable patient volumes, limited recruitment resources, or specific after-hours coverage requirements may find outsourced staffing more practical.</p>



<p class="wp-block-paragraph">Before choosing a staffing arrangement, administrators should evaluate:</p>



<ol start="1" class="wp-block-list">
<li>The number of psychiatric hours required each week.</li>



<li>The need for daytime, evening, overnight, and weekend coverage.</li>



<li>Whether services should be delivered virtually, in person, or through a combination of both.</li>



<li>The availability of specialty psychiatric professionals.</li>



<li>Credentialing, licensing, and medical staff requirements.</li>



<li>The total cost of outsourced coverage compared with direct employment.</li>
</ol>



<p class="wp-block-paragraph">A carefully structured staffing arrangement can help facilities balance clinical needs, patient access, and financial sustainability.</p>



<h2 class="wp-block-heading">Conclusion</h2>



<p class="wp-block-paragraph">Healthcare organizations do not always need to employ a full-time psychiatrist to provide dependable psychiatric services. With outsourced psychiatric staffing, hospitals, clinics, and substance use disorder facilities can access qualified professionals according to their specific requirements.</p>



<p class="wp-block-paragraph">The combination of telepsychiatry, flexible scheduling, and established psychiatric provider networks offers a practical way to address workforce shortages while managing staffing expenses.</p>



<p class="wp-block-paragraph">For organizations seeking to expand psychiatric services, improve after-hours coverage, or access specialty psychiatric professionals without committing to additional permanent positions, partnering with an experienced provider such as FasPsych can be a valuable option.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>7 Top Agentic AI Drug Discovery Solutions</title>
		<link>https://medchrome.com/extras/top-agentic-ai-drug-discovery-solutions/</link>
		
		<dc:creator><![CDATA[Editor]]></dc:creator>
		<pubDate>Sat, 31 Oct 2026 02:33:23 +0000</pubDate>
				<category><![CDATA[Extras]]></category>
		<guid isPermaLink="false">https://medchrome.com/?p=14790</guid>

					<description><![CDATA[Key Takeaways The word agentic arrived in drug discovery faster than any shared definition of it. A system that reads ten thousand papers and proposes [&#8230;]]]></description>
										<content:encoded><![CDATA[
<h2 class="wp-block-heading"><strong>Key Takeaways</strong></h2>



<ul class="wp-block-list">
<li>Only three of the seven platforms here use the word agent about themselves, so the category label sorts vendors far less reliably than two concrete questions do.</li>



<li>Converge Bio ranks first for a team that intends to maintain its own pipeline, closing the loop on managed wet-lab validation while holding no drug assets.</li>



<li>The hardest physical loops in this market belong to vendors advancing their own molecules, which makes autonomy and independence difficult to buy together.</li>



<li>Every performance figure in this category is vendor-reported, so method disclosure matters more than headline multiples when comparing claims.</li>
</ul>



<p class="wp-block-paragraph">The word agentic arrived in drug discovery faster than any shared definition of it. A system that reads ten thousand papers and proposes a target is called an agent. So is a model that generates a sequence in one pass, and so is a robot arm running a protocol somebody else wrote. FutureHouse, the nonprofit research lab behind several of the field&#8217;s best-known agents, draws the line usefully: an AI scientist &#8220;actually runs a loop: it builds a model of the world, generates hypotheses from that model, tests them, and updates the model based on new data.&#8221; The same page adds the sentence most vendors leave out: no system has fully cleared that bar yet, including theirs.</p>



<h2 class="wp-block-heading"><strong>At a Glance</strong></h2>



<ol class="wp-block-list">
<li>Converge Bio: antibody design whose loop closes on managed wet-lab validation for the customer&#8217;s own pipeline</li>



<li>Edison Scientific: the most literal agent here, steering and branching investigations mid-run</li>



<li>CytoReason: the only named, dated agent product in the category, built on computational disease models</li>



<li>Deep Origin: agent-branded tools plus software a customer&#8217;s own team runs</li>



<li>Terray Therapeutics: an industrial measurement engine feeding a fully closed chemistry loop</li>



<li>Chemify: robotic synthesis driven by a chemical programming language</li>



<li>Turbine: simulation at scale deciding which few experiments reach a bench</li>
</ol>



<h2 class="wp-block-heading"><strong>What Separates a Real Loop From a Good Prediction</strong></h2>



<p class="wp-block-paragraph">Before comparing features, settle what the system is allowed to do and what it does with the answer:</p>



<ul class="wp-block-list">
<li><strong>Planning versus one-shot output.</strong> An agent chooses its next action. A generative model returns candidates and stops. Both are useful, and only one of them changes course when a result disappoints.</li>



<li><strong>The physical gap.</strong> Most systems marketed as agents cannot touch an experiment. Hypotheses, analysis and even figures can be machine-generated while human hands do everything at the bench.</li>



<li><strong>Who holds the output.</strong> A vendor running its own discovery programs  is a competitor for the same molecules, however good the tooling it sells alongside.</li>
</ul>



<p class="wp-block-paragraph">Answer those three, and the roster below sorts itself without reference to the word &#8220;agentic&#8221; at all.</p>



<h2 class="wp-block-heading"><strong>7 Top Agentic AI Drug Discovery Solutions</strong></h2>



<h3 class="wp-block-heading"><strong>1. Converge Bio</strong></h3>



<p class="wp-block-paragraph"><a href="https://converge-bio.com/"><u>Converge Bio</u></a> is the best agentic AI drug discovery solution for a team that intends to keep its own pipeline, because its loop closes on wet-lab evidence and it builds no drugs of its own. ConvergeAB takes a sequence for optimization, a target product profile and an antigen sequence and structure, then optimizes affinity, stability, solubility, immunogenicity and expression in a single design pass across IgG, scFv, VHH and bispecific formats.</p>



<p class="wp-block-paragraph">Eight capabilities are named, including affinity maturation, developability and expression optimization, humanization, cross-reactivity tuning, pH-dependent binding, and both IP generation and IP fortification. The model is trained on a trillion natural protein tokens, seven million antibody sequences, three million antibody-antigen pairs and a hundred thousand fully characterized antibodies.</p>



<p class="wp-block-paragraph">What places it first is the shape of the engagement, not the model. Tens to hundreds of thousands of in silico candidates are narrowed to roughly forty-eight for screening per round, on a six-week iterate-and-refine cycle, and Converge manages the wet-lab validation through partner CROs rather than handing over a file. Its own description is working as an AI-Lab partner in a closed loop until the customer&#8217;s team has validated, development-ready solutions.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Multi-property optimization that raises, lowers or holds each property as a programme requires</li>



<li>Wet-lab validation managed through partner CROs on a roughly six week design cycle</li>



<li>Private customer instance, with customer data excluded from base-model training</li>



<li>No internal drug pipeline, so the platform competes for no molecules of its own</li>



<li>Antibody formats spanning IgG, scFv, VHH and bispecifics</li>
</ul>



<h3 class="wp-block-heading"><strong>2. Edison Scientific</strong></h3>



<p class="wp-block-paragraph">Edison Scientific publishes the most literal agentic description in this market. Its Kosmos system reads literature, analyses data, generates hypotheses, steers investigations mid-run, branches hypotheses and executes workflows autonomously, built on what the company calls structured world models. A single run is described as reading 1,500 papers and running 42,000 lines of analysis code, with the agent provisioning its own compute for docking.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Mid-run steering and hypothesis branching rather than one-shot generation</li>



<li>On-premise deployment with SOC 2 Type II and integration into existing lab data systems</li>



<li>Published accuracy rate and documented failure modes</li>



<li>Named pharmaceutical partnership with Incyte, with no financial terms disclosed</li>
</ul>



<h3 class="wp-block-heading"><strong>3. CytoReason</strong></h3>



<p class="wp-block-paragraph">CytoReason offers the only named and dated agent product in this comparison. LINA, announced in January 2026, is described as an AI agent for pharmaceutical research and development, accelerated by NVIDIA and built on the company&#8217;s computational disease models. It is trained on hundreds of drug-development questions used across the industry, produces grounded analysis plans with reproducible code, and the company references scalable multi-agent scientific workflows.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>A named, dated agent product built on validated computational disease models</li>



<li>Reproducible analysis code and grounded analysis plans as outputs</li>



<li>Deep named pharmaceutical evidence including Pfizer, Sanofi and Takeda</li>



<li>Delivered through collaboration and licensing rather than self-serve access</li>
</ul>



<h3 class="wp-block-heading"><strong>4. Deep Origin</strong></h3>



<p class="wp-block-paragraph">Deep Origin is the entry that most resembles software a customer actually operates. Its platform spans docking, free energy perturbation and ADMET prediction, reached three ways: a subscription starting at thirty-two dollars a month, a code-first API, and research partnerships with milestones and optional IP co-ownership. DO Patent is described outright as an AI agent that extracts full molecular structures from patents and scientific PDFs.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Self-serve subscription and a code-first API, unusual in this category</li>



<li>Agent-branded patent extraction and a conversational discovery assistant</li>



<li>Physical loop pursued through a named ARIA programme with a robotics partner</li>



<li>Academic users named in page text, with pharmaceutical logos reflecting team history</li>
</ul>



<h3 class="wp-block-heading"><strong>5. Terray Therapeutics</strong></h3>



<p class="wp-block-paragraph">Terray has the most convincing physical loop here and the hardest numbers behind it, which is why it belongs in the list despite claiming nothing agentic at all. Its EMMI platform combines ultra-miniaturized molecule testing hardware with a highly automated laboratory and a full-stack AI layer, grounded in a dataset the company puts at fourteen billion unique target-molecule measurements, growing by roughly a billion per quarter. Its COATI3 foundation model is trained on over a billion diverse molecules.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Fourteen billion target-molecule measurements generated in its own automated lab</li>



<li>COATI3 foundation model trained on over a billion molecules</li>



<li>Named partnered programs  with Bristol Myers Squibb, Gilead and Odyssey Therapeutics</li>



<li>Internal pipeline advancing alongside partner work</li>
</ul>



<h3 class="wp-block-heading"><strong>6. Chemify</strong></h3>



<p class="wp-block-paragraph">Chemify closes a physical loop in its own facility, and does it in chemistry rather than biology. Its chemputation approach translates target molecules into chemical code that runs directly on robotic systems, enabling what the company describes as fully automated design-make-test-analyse cycles that remove the synthesis bottleneck. The stack includes an ASSEMBLER layer for route optimization, a chemputability score for whether a molecule can actually be made, and a universal chemical programming language.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Robotic synthesis at gram scale in its own Glasgow facility</li>



<li>A chemical programming language encoding reproducible synthesis plans</li>



<li>Makeability scoring before synthesis is attempted</li>



<li>Three peer-reviewed validation papers published in April 2026</li>
</ul>



<h3 class="wp-block-heading"><strong>7. Turbine</strong></h3>



<p class="wp-block-paragraph">Turbine is the clearest counter-example in this list, and that is precisely its value. Its vLab platform runs what the company puts at more than fifty million virtual experiments per day against a Virtual Cell model, so the small number of physical experiments that follow carry the highest probability of success. The company does not use agent language, describing the mechanism instead as an active learning loop in which simulations inform the right wet-lab experiments, with scientists designing and interpreting those virtual experiments.</p>



<p class="wp-block-paragraph"><strong>Key features:</strong></p>



<ul class="wp-block-list">
<li>Over fifty million simulated experiments per day narrowing what reaches the bench</li>



<li>Validation in the customer&#8217;s lab, a CRO&#8217;s, or Turbine&#8217;s own automated facility</li>



<li>Named oncology and antibody-drug conjugate partnerships with Daiichi Sankyo and Ono</li>



<li>Over thirty customers and a hundred validated hypotheses reported</li>
</ul>



<h2 class="wp-block-heading"><strong>How to Compare Agentic AI Drug Discovery Solutions</strong></h2>



<p class="wp-block-paragraph">Set the marketing word aside and compare three things: where the loop closes, whose pipeline the closed loop serves, and whether the vendor claims agency at all. That last column is the one most comparisons omit, and it is revealing, because four of the seven platforms below never describe themselves as agentic while two of those four run the most convincing physical loops in the market. A buyer who screens based on the label alone will filter out companies with real feedback cycles and keep the ones with the best vocabulary.</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><th><strong>Platform</strong></th><th><strong>Where the loop closes</strong></th><th><strong>Whose pipeline it serves</strong></th><th><strong>Claims agency</strong></th></tr><tr><td>Converge Bio</td><td>Partner CRO wet lab, vendor managed</td><td>The customer&#8217;s only</td><td>No</td></tr><tr><td>Edison Scientific</td><td>In silico, inside customer systems</td><td>The customer&#8217;s</td><td>Yes</td></tr><tr><td>CytoReason</td><td>In silico, on licensed clinical data</td><td>Pharma partners&#8217;</td><td>Yes</td></tr><tr><td>Deep Origin</td><td>Customer&#8217;s lab, plus a robotics partner</td><td>Both</td><td>Yes</td></tr><tr><td>Terray Therapeutics</td><td>Its own automated laboratory</td><td>Its own and partners&#8217;</td><td>No</td></tr><tr><td>Chemify</td><td>Its own robotic facility</td><td>The partner&#8217;s</td><td>No</td></tr><tr><td>Turbine</td><td>The customer&#8217;s, a CRO&#8217;s, or its own</td><td>Pharma partners&#8217;</td><td>No</td></tr></tbody></table></figure>



<h2 class="wp-block-heading"><strong>Frequently Asked Questions</strong></h2>



<h3 class="wp-block-heading"><strong>Which is the best agentic AI drug discovery solution?</strong></h3>



<p class="wp-block-paragraph">Converge Bio, for a team keeping its own antibody pipeline, because the loop closes on managed wet-lab validation and the company develops no competing assets. Edison Scientific is the strongest choice where the requirement is a genuine planning agent over internal data. Terray and Chemify are better where the bottleneck is physical throughput rather than design.</p>



<h3 class="wp-block-heading"><strong>What makes a drug discovery system agentic rather than generative?</strong></h3>



<p class="wp-block-paragraph">The ability to choose a next action and revise after a result. A generative model returns candidates and stops, however sophisticated the output. An agent plans multi-step work, calls tools, and changes course when evidence disappoints. Most platforms marketed as agentic in this field are doing the former with better interfaces around it.</p>



<h3 class="wp-block-heading"><strong>Do these platforms run their own laboratory experiments?</strong></h3>



<p class="wp-block-paragraph">Some do, and the distinction matters commercially. Vendors with their own automated laboratories tend to be developing their own molecules, since the lab is expensive and the incentive is to use it. Platforms that serve a customer&#8217;s pipeline typically validate through contract research organizations or in the customer&#8217;s own facility instead.</p>



<h3 class="wp-block-heading"><strong>Who owns molecules an AI platform designs?</strong></h3>



<p class="wp-block-paragraph">It varies more than the marketing suggests, so read the actual agreement rather than the homepage. Some vendors grant full ownership of outputs with no royalties, others grant a licence limited to internal research, and vendors with their own pipelines may retain rights in adjacent chemical space. Check whether separate terms govern separate tools.</p>



<h3 class="wp-block-heading"><strong>How much of this performance data is independently verified?</strong></h3>



<p class="wp-block-paragraph">Very little of it. Almost every figure in this market is vendor-generated, often labelled internal benchmarking, and frequently published as a preprint authored by the company&#8217;s own scientists. That does not make the numbers wrong, but it means method disclosure is the better signal: a vendor publishing assay conditions and failure cases is easier to assess than one publishing a multiple.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>MT1 vs MT2: How the Two Melanotan Research Peptides Differ in the Lab</title>
		<link>https://medchrome.com/extras/mt1-vs-mt2-how-the-two-melanotan-research-peptides-differ-in-the-lab/</link>
		
		<dc:creator><![CDATA[Editor]]></dc:creator>
		<pubDate>Thu, 22 Oct 2026 01:16:07 +0000</pubDate>
				<category><![CDATA[Extras]]></category>
		<guid isPermaLink="false">https://medchrome.com/?p=14788</guid>

					<description><![CDATA[Few research compounds attract as much loose talk as the melanotan peptides, yet the underlying chemistry is far more modest than the chatter suggests. These [&#8230;]]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Few research compounds attract as much loose talk as the melanotan peptides, yet the underlying chemistry is far more modest than the chatter suggests. These are laboratory molecules that originated in a university setting, and the plain record of what they are is more interesting than any online promise. Vive Peptides, a US-based supplier of research-grade peptides, lists them strictly as research materials. Its compounding takes place at a US-based lab that works to cGMP requirements, and its certificate library covered 25 peptides with 126 certificates as of October 2026.</p>



<p class="wp-block-paragraph">This explainer compares MT1 and MT2 purely as research peptides: what each one is, how their structures differ, and what the public chemistry records show. Vive Peptides sells both compounds, like everything else in its catalog, strictly for laboratory and research use only, and none of it is approved for human consumption. Readers in medicine and nursing will recognize the habit of separating a reagent&#8217;s identity from any claim about people, and that habit guides everything below.</p>



<h2 class="wp-block-heading">What separates MT1 from MT2 at the structural level?</h2>



<p class="wp-block-paragraph">The separation is structural: MT1 is a linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH), whereas MT2 is a ring-closed heptapeptide analog of that same hormone. Melanotan I is a straight chain carrying norleucine at position 4 and D-phenylalanine at position 7, while Melanotan II folds part of its seven-residue sequence into a ring. Think of a peptide as a chain of amino acids. A linear chain has two free ends and can flex along its whole length; a ring restricts how the molecule can fold.</p>



<p class="wp-block-paragraph">Chemists care because shape governs how a ligand meets its receptor. A ring-shaped analog and a straight-chain analog are different probes, so results obtained with one should not be assumed to carry over to the other. The table sets out the contrast as it is framed in research and in the PubChem entries covered further down.</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><th>Feature</th><th>MT1</th><th>MT2</th></tr><tr><td>Structure</td><td>Linear alpha-MSH analog</td><td>Ring-closed heptapeptide analog of alpha-MSH</td></tr><tr><td>Sequence detail</td><td>Norleucine at position 4, D-phenylalanine at position 7</td><td>Seven-residue sequence with part of it closed into a ring</td></tr><tr><td>Receptor framing</td><td>MC1R and related melanocortin receptors</td><td>Non-selective across melanocortin receptors</td></tr><tr><td>CAS registry number</td><td>75921-69-6</td><td>121062-08-6</td></tr></tbody></table></figure>



<h2 class="wp-block-heading">Where did the melanotan peptides originate?</h2>



<p class="wp-block-paragraph">They originated at the University of Arizona in the 1980s. In 1984, Mac E. Hadley, working with chemist Victor Hruby and his students, synthesized highly active analogs of alpha-MSH there. The logic of an analog is simple: retain the recognizable core of a natural signaling molecule, then modify it so that it becomes a separate experimental object that can be compared with the original. Melanotan I is the linear version and Melanotan II the ring-closed one.</p>



<p class="wp-block-paragraph">That lineage accounts for the naming and for the lasting academic interest. It also explains why this family sits in a catalog of research reagents, alongside other tools for mapping receptor biology, rather than on a shelf of consumer goods. A university pedigree is a reason for curiosity, not a permission slip.</p>



<h2 class="wp-block-heading">How does a research listing describe MT2?</h2>



<p class="wp-block-paragraph">It describes the material in plain bench terms, and the MT2 entry makes a useful working example. The <a href="https://vivepeptides.com/product/melanotan-2-mt2/">Vive Peptides MT2</a> listing describes a 10 mg research vial of Melanotan 2 acetate, registered under CAS 121062-08-6. The material is a white to off-white freeze-dried powder, and its mechanism class is given as a non-selective melanocortin receptor agonist, which is laboratory shorthand and nothing more.</p>



<p class="wp-block-paragraph">Selectivity is the informative part of that phrase. A probe framed around a single receptor and a probe that engages the whole family answer different questions. The term non-selective signals the second kind of tool: a molecule meant to engage several melanocortin receptors at once rather than one in isolation. MT1 is framed around MC1R and related receptors, so the two peptides give a research team a pair to compare side by side in the same assay.</p>



<h2 class="wp-block-heading">What do registry numbers and receptor cloning reveal about the two peptides?</h2>



<p class="wp-block-paragraph">They show that MT1 and MT2 are two distinct, well-indexed chemical entities that engage one shared receptor family. PubChem, the open chemistry database run by the US National Center for Biotechnology Information (NCBI), indexes these research peptides under the same CAS registry numbers the product pages give: 75921-69-6 for Melanotan 1 and 121062-08-6 for melanotan II. A registry number works as an identity tag for a molecule, so two different numbers confirm two separate compounds rather than one product sold under two names.</p>



<p class="wp-block-paragraph">The receptor side has its own landmark. The genes for the melanocortin receptors, including MC1R, were cloned and reported in Science in 1992 by Kathleen Mountjoy, Lisa Robbins, Mark Mortrud and Roger Cone. MC1R signaling steers melanocytes toward eumelanin, the dark pigment, rather than pheomelanin, the red-yellow one, and the receptor recurs in pigmentation research in cell culture and animal models. Statements like these describe what a laboratory does with a reagent. They say nothing about what any compound might do in a person, and this article will not suggest otherwise.</p>



<p class="wp-block-paragraph">At the bench, the comparison reduces to four points:</p>



<ul class="wp-block-list">
<li>MT1: linear structure, indexed under CAS 75921-69-6.</li>



<li>MT2: ring-closed structure, indexed under CAS 121062-08-6.</li>



<li>Shared target family: melanocortin receptors, with MC1R as the member followed here.</li>



<li>Shared status at the supplier: strictly for laboratory and research use only.</li>
</ul>



<h2 class="wp-block-heading">Why are these peptides sold strictly for laboratory use?</h2>



<p class="wp-block-paragraph">Because they are research reagents rather than approved consumer products, and the label should say so plainly. The supplier sells these peptides strictly for laboratory and research use only, not for human consumption or veterinary use. Every product page carries a Research Use Only notice stating that the items are not approved for human consumption and that nothing on the page is medical advice. That label does real work: it tells a reader what the item is, what it is meant for, and what it is not.</p>



<p class="wp-block-paragraph">A word about online hype belongs here too. The internet is full of confident claims about melanocortin peptides: forum threads, social clips, anonymous posts, secondhand stories. Almost none of it comes from controlled research, and none of it comes with accountability. A research label is not a loophole, and a stranger&#8217;s anecdote is not evidence. Unregulated personal use of laboratory chemicals carries unknown risks, and this article deliberately gives no usage details, because none belong in a piece about research materials. Anyone curious about their own body or appearance should talk with a licensed clinician and rely on products that are actually approved for the purpose, not on reagents made for the bench.</p>



<h2 class="wp-block-heading">What should a reader take from the MT1 and MT2 comparison?</h2>



<p class="wp-block-paragraph">MT1 and MT2 are alpha-MSH analogs from a University of Arizona research tradition, one linear and one ring-closed, used by laboratories to examine melanocortin receptors in cell and animal models. The public record supports the distinction: PubChem indexes each under its own CAS number, and the receptor family they probe was cloned and reported in Science in 1992. Both are listed strictly for laboratory and research use only, and that frame is the one worth keeping. Appreciate the chemistry, discount the hype, and leave laboratory reagents in the laboratory.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>HD Liposculpture: How Surgeons “Draw” Abs Without the Gym</title>
		<link>https://medchrome.com/extras/hd-liposculpture-how-surgeons-draw-abs-without-the-gym/</link>
		
		<dc:creator><![CDATA[Editor]]></dc:creator>
		<pubDate>Wed, 30 Sep 2026 10:16:10 +0000</pubDate>
				<category><![CDATA[Extras]]></category>
		<guid isPermaLink="false">https://medchrome.com/?p=14784</guid>

					<description><![CDATA[The Universal Fitness Plateau You know the frustration: you train regularly, watch your diet and still have a stubborn layer of fat covering your abdominal [&#8230;]]]></description>
										<content:encoded><![CDATA[
<h2 class="wp-block-heading">The Universal Fitness Plateau</h2>



<p class="wp-block-paragraph">You know the frustration: you train regularly, watch your diet and still have a stubborn layer of fat covering your abdominal muscles.</p>



<p class="wp-block-paragraph">For some people, that final layer simply does not disappear, no matter how disciplined their workouts are. Genetics, fat distribution and skin quality all play a role. <strong>HD liposculpture is designed to address this last layer and make existing muscle definition more visible.</strong></p>


<div class="wp-block-image">
<figure class="aligncenter size-large is-resized"><a href="https://medchrome.com/wp-content/uploads/2026/09/fit-man-scaled.webp"><img fetchpriority="high" decoding="async" width="1024" height="572" src="https://medchrome.com/wp-content/uploads/2026/09/fit-man-1024x572.webp" alt="" class="wp-image-14785" style="width:600px;height:auto" srcset="https://medchrome.com/wp-content/uploads/2026/09/fit-man-1024x572.webp 1024w, https://medchrome.com/wp-content/uploads/2026/09/fit-man-1536x857.webp 1536w, https://medchrome.com/wp-content/uploads/2026/09/fit-man-767x428.webp 767w, https://medchrome.com/wp-content/uploads/2026/09/fit-man-300x167.webp 300w, https://medchrome.com/wp-content/uploads/2026/09/fit-man-2048x1143-1.webp 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
</div>


<h2 class="wp-block-heading">Traditional Lipo vs. 3D Body Etching</h2>



<p class="wp-block-paragraph">Traditional liposuction is primarily about removing excess fat and reducing volume. The goal is a smoother, slimmer contour.</p>



<p class="wp-block-paragraph">HD liposculpture takes a more detailed approach. Instead of treating the abdomen as one area, the surgeon works around individual anatomical structures, selectively removing and preserving fat to create more visible muscle contours.</p>



<p class="wp-block-paragraph">This is why the technique is often described as <strong>body etching</strong>: the surgeon is not simply making the waist smaller but using changes in fat thickness to create natural-looking highlights and shadows.</p>



<p class="wp-block-paragraph">To understand how this approach is used in modern body contouring, you can explore these <a href="https://drzykov.com/body/liposculpture.html">modern liposculpture techniques</a>.</p>



<h2 class="wp-block-heading">The Art of Creating Definition</h2>



<p class="wp-block-paragraph">The procedure starts with careful mapping of the patient&#8217;s anatomy. Before surgery, the surgeon identifies the natural lines and boundaries created by the abdominal muscles.</p>



<p class="wp-block-paragraph">Specialized cannulas are then used to remove fat from selected areas. The surgeon may emphasize the linea alba, the vertical line between the abdominal muscles, as well as the borders of the rectus abdominis and the oblique muscles.</p>



<p class="wp-block-paragraph"><strong>The goal is not to carve deep lines into the abdomen.</strong> Instead, carefully controlled differences in fat thickness create shadows that make the underlying muscles easier to see.</p>



<p class="wp-block-paragraph">The result depends heavily on the patient&#8217;s existing anatomy. Someone with well-developed abdominal muscles may achieve much more visible definition than someone with little underlying muscle, even if both undergo the same procedure.</p>



<h2 class="wp-block-heading">Safety, Pain and the Fear of a “Plastic” Look</h2>



<p class="wp-block-paragraph">The idea of surgically sculpting the abdomen naturally raises concerns. Patients often worry about pain, complications, uneven contours or ending up with an obviously operated-on appearance.</p>



<p class="wp-block-paragraph">Modern liposuction techniques can use technologies such as ultrasound or radiofrequency-assisted devices, depending on the surgeon and procedure. These technologies are designed to facilitate fat removal and may influence bruising, swelling and recovery, but they do not eliminate surgical risks.</p>



<p class="wp-block-paragraph">The final appearance also depends on how much fat is removed and where it is left behind. <strong>Overly aggressive sculpting can create unnatural grooves and contour irregularities.</strong> For that reason, precision and restraint are just as important as fat removal itself.</p>



<h2 class="wp-block-heading">The Ideal Candidate: Enhancement, Not Weight Loss</h2>



<p class="wp-block-paragraph">HD liposculpture is not a weight-loss procedure. It is intended for people who are already relatively close to their target weight but have localized fat that hides otherwise defined contours.</p>



<p class="wp-block-paragraph"><strong>The surgeon is refining the body you already have, not creating a fitness transformation from scratch.</strong></p>



<p class="wp-block-paragraph">Patients with significant amounts of visceral fat, substantial loose skin or a higher level of overall body fat may need a different approach. A consultation is necessary to determine whether liposculpture alone can achieve the desired result.</p>



<h2 class="wp-block-heading">Recovery and Maintaining the Result</h2>



<p class="wp-block-paragraph">Recovery varies depending on the extent of the procedure and the techniques used. Swelling, bruising, tenderness and temporary changes in sensation are common during the early healing period. Compression garments are often recommended, and strenuous exercise is usually restricted until the surgeon considers it safe to resume.</p>



<p class="wp-block-paragraph">The abdomen can continue changing for several months as swelling decreases and the tissues settle. <strong>The early postoperative appearance is not the final result.</strong></p>



<p class="wp-block-paragraph">And there is still a role for the gym. Liposculpture can reveal muscle contours, but it cannot replace muscle development or protect against future weight gain. Significant changes in body weight can alter the result.</p>



<p class="wp-block-paragraph"><strong>HD liposculpture can reveal the definition that diet and exercise alone may not fully show, but maintaining that definition remains a long-term commitment.</strong></p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>